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higher than for FDG-GTV. There was no significant 
differences in the volumes calculated from FLT-GTV and FDG-
GTV (45,38±47,48 vs 47,67±36,44; p=0,236).  
There was correlation between FLT volume vs FDG volume 
(R=0,7, p<0,001) and there was weak correlation between 
FDG SUVmax and level of hemoglobin (R=0,397, p=0,03). 
Analysis of other clinical and metabolic parameters were not 
significant. There were no differences observed in clinical 
and metabolic parameters in patients with lymph node 
involvement or with FIGO III. Clinical Target Volume always 
enclosed both FLT and FDG PET GTV volume. 
Conclusions: In this sample size study FLT-GTV shows the 
same volumes but lower SUVmax of thimidine within tumor 
mass as compared to glucose metabolism providing similar 
CTV for radiation therapy. There was no difference between 
tumor tracer uptake in patients with local disease and with 
lymph nodes involvement. FLT imaging may have additional 
potential role in the evaluation of tumor response to therapy 
as it shows proliferation processes.  
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Purpose/Objective: A CCD-based EPID using new crystal-
assembly X-ray (CAX) converters is investigated for 
radiotherapy dosimetry. The proposed EPID design consists in 
replacing the common phosphor X-ray converters of current 
CCD-based EPIDs with high-stopping-power CAX converters. A 
Test Imaging Device (TID), consisting of a 30-mm-thick CAX 
converter made of Bismuth Germanate (BGO), coupled to a 
highly sensitive CCD camera, was used to evaluate the 
accessible imaging and dosimetric performance of the 
proposed design. The system response to dose and its 
dependence on photon beam energy were investigated. The 
effects of ghosting, dose rate, field size and phantom 
thickness were evaluated as well. The same measurements 
were also performed with our clinically used aSi-EPID so that 
comparisons of performance could be directly inferred. 
Materials and Methods: All measurements were performed 
on an Elekta linear accelerator; model Precise. The aSi-EPID 
was an Elekta iViewGT. A calibrated 0.3 cm3 thimble-type 
PTW ionization chamber and a Wellhofer electrometer were 
used for the dose measurements. 
The test Imaging Device includes a highly sensitive, low-
noise, thermoelectrically cooled, 16-bit CCD camera 
equipped with a photographic lens and a mirror used to place 
the CCD camera out of the direct X-ray beam. The 
scintillator, used to convert the X-ray image into visible light, 
was a 30-mm-thick, 165 x 165 mm2 dimension, crystal-
assembly X-ray converter made of two BGO crystal plates and 
manufactured by Saint-Gobain Crystals. The CCD camera was 
manufactured by Princeton Instruments (Trenton, New 
Jersey, USA), model PIXIS 2048B. The CCD sensor, 27.6 x 27.6 
mm2 in dimension, is made of 2048 x 2048, 13.5 µm square 
pixels.  
Results: The TID displayed no detectable ghosting or 
sensitivity to dose rate. Its response to MU exposure was 
found to be linear within about ± 1%. The level of glare 
induced in the TID and the aSi-EPID were equivalent. The TID 
resolution was higher than that of the aSi-EPID on the axis, 
but was found to decrease with off-axis distance. Finally, the 
image quality, assessed on the basis of signal-to noise ratio in 
low dose radiographs of the larynx of a patient, was higher 
for the TID. 
Conclusions: The imaging performance accessible with the 
crystal-assembly X-ray converter proved to be satisfying and 
its dosimetric capability was found to be superior to that of 
the current aSi-EPID. The proposed design should be further 
investigated with a fully representative prototype, i.e. a 
larger-dimension CAX converter installed in a modern CCD-
based EPID in place of the metal/phosphor converter. Either 
BGO or LYSO scintillating crystal could be used to build the 
CAX converter: it may actually be useful to evaluate both 
configurations in order to identify the best suited crystal for 
clinical use.  
   
PD-0443   
Clinical evaluation of an innovative ionization chamber 
technology for patient quality assurance 
M. Togno1,2,3, D. Menichelli3, O. Morin4, M. Oechsner1, J.J. 
Wilkens1,2 
1TU München, Klinikum rechts der Isar, Radiation Oncology  
2TU München, Physik-Department, München, Germany  
3IBA Dosimetry GmbH, Department of Innovation and Physics, 
Schwarzenbruck, Germany  
4University of California San Francisco, Radiation Oncology, 
San Francisco, USA  
 
Purpose/Objective: To prove the feasibility of a new 
ionization chamber technology with high spatial resolution 
for patient plan quality assurance in complex MV X-ray 
radiotherapy techniques such as IMRT and VMAT. 
Materials and Methods: The prototype under test is a linear 
array of air vented ionization chambers developed by IBA 
Dosimetry GmbH, consisting of 80 pixels with 3.5 mm spatial 
resolution and 4 mm3 sensitive volume. The detector was 
tested in a plastic phantom, performing a comparative 
clinical evaluation of treatment plans for a variety of clinical 
localizations and techniques. Treatment plans were delivered 
with two different accelerators: a Varian Trilogy (Klinikum 
rechts der Isar, Dept. of Radiation Oncology, Munich) and a 
Varian True Beam (UCSF, Dept. of Radiation Oncology, San 
Francisco) both equipped with a HD120 MLC. The 
characterization was performed for VMAT, IMRT and SBRT 
treatment plans with different beam qualities (6 MV and 15 
MV) and dose rates up to 1000 MU/min. A CT scan of the 
detector in the phantom was acquired and imported in the 
Varian Eclipse TPS in order to compare the planned dose 
distribution with the measured one. Other reference 
detectors used for comparison were radiochromic films (RCF) 
and a commercial array based on diode technology. 
Results: The ionization chamber linear array was found to be 
in very good agreement with the reference detectors for all 
different clinical evaluations. Due to the 3.5 mm spatial 
resolution, even dose distributions with steep gradients are 
very well defined and the average difference with the 
expected dose from TPS was less than 1%. Moreover, the 
detector insensitivity on dose per pulse in conjunction with 
the low energy dependence typical of ionization chambers 
lead to high performances even when therapy beams feature 
extremely modulated dose rate and different qualities.  
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Example of patient QA: Varian Trilogy linac with HD120 MLC, 
VMAT delivery technique (lung tumor), 15 MV beam quality, 
~6 Gy overall dose. 
Conclusions: The technology has been proven to be valuable 
for patient plan quality assurance of complex fields through 
an extensive clinical investigation considering different 
irradiation techniques. High dosimetric performance was 
achieved in the verification of therapy beams due to high 
spatial resolution, insensitivity on dose per pulse and energy 
independence. The new ionization chamber technology is 
intended to be used in future 2D detectors.  
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Purpose/Objective: Low energy proton beam could be of 
potential interest for radiation treatments of shallow lesions 
due to expected higher relative biological effectiveness (RBE) 
and sharp dose fall-off beyond target volume. We designed 
and performed output measurements for RBE using EBT3 
model GafChromicTM film. 
Materials and Methods: Figure 1.a represents experimental 
setup used to measure depth dose curve (Fig.1.b) and beam 
output using a calibrated PTW Markus ion chamber. To 
improve stability of irradiation beam (26.5 MeV protons) from 
cyclotron CS30, an aluminum cylinder was added in front of 
the beam serving as a timed shutter. As beam's energy 
decreases with depth, measurement depth was scaled using 
ratio of continuous slowing down approximation (CSDA) 
ranges at each point. Measured signal, corrected by monitor 
chamber reading, was scaled by ratio of stopping powers at a 
given depth for water and air divided by the same ratio in 
Cobalt. Output was measured at 3 mm depth in the middle of 
plateau ahead of the Bragg peak, and PDD was normalized at 
the same depth. Following the TRS398 reference dosimetry 
protocol for proton beams, output was measured in water in 
terms of Gy/nC where nC is reading of the monitor chamber. 
Once the output was known, we calibrated EBT3 film model 
for doses up to 35 Gy (Fig.1.c) by irradiating film pieces in 
Solid WaterTM at depth of 3 mm and converting depth to 
water. For RBE determination, attached breast cell cultures 
(MCF-7, MCF-12, MDA-MB-231) in 96-well plates were 
irradiated by the horizontal beam (Fig.1.d). Behind the plate, 
a piece of film was placed to monitor dose distribution during 
experiment. The MTT colorimetric dye assay was used to 
assess cell survival (proliferation inhibition) following 
irradiation. 
Results: Depending on the cyclotron current and collimator 
to surface distance (CSD), outputs ranged approximately from 
6.8 Gy/s (10 nA, 165 cm CSD) to 500 Gy/s (100 nA, 75 cm 
CSD). For each irradiated 96-well plate, a dose image was 
reconstructed (Fig.1.e) and then scaled by the measured PDD 
data. Natural Gaussian shape of the beam was used to obtain 
multiple dose points within the plate from single exposure. 
Average doses (per well) were used to construct the survival 
fraction (Fig.1.f). The average RBE of proton beam compared 
to x-ray at the 50% inhibitory dose was 1.22 (SD = 0.05), 
which was statistically higher (P = 0.02) than the 1.1 
reported for standard proton therapy. 
Conclusions: We described a radiochromic film-based dose 
monitoring system that can be used for colorimetric 
radiobiology assays with low energy proton beams. The 
relatively higher RBE would be promising for treatment of 
low laying lesions. Having a sharp dose fall-off behind the 
Bragg peak, high dose rate proton beam originating from a 
production cyclotron could further allow for dose escalation 
protocols in the case of superficial diseases or during intra-
operative radiotherapy procedures. Supported by NSTIP 11-
BIO1428-20. 
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Purpose/Objective: To investigate the feasibility of back-
projection portal dosimetry for accurate in vivo 3D 
dosimetric verification of Volumetric Modulated Arc Therapy 
(VMAT) prostate treatments by an EPID gantry angle-resolved 
data acquisition, throught the calculation of patient 
transmission. 
The novel approach is analysing data by dose volume 
histograms (DVH), that provide information on actual 
delivered dose to the tumor volume and surrounding critical 
structures. 
